Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4873 - Functional genomic mRNA (FGmRNA) profiling of >18,000 tumor samples identifies potential new indications for antibody-drug conjugates (ADCs) in a broad range of tumor types

Date

11 Sep 2017

Session

Poster display session

Presenters

Kirsten Moek

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

K.L. Moek, D.J. de Groot, E.G..E. de Vries, R.S.N. Fehrmann

Author affiliations

  • Medical Oncology, University Hospital Groningen (UMCG), 9700 RB - Groningen/NL
More

Resources

Abstract 4873

Background

ADCs, consisting of an antibody designed against a specific antigen at the cell membrane linked with a cytotoxic agent, are an emerging class of therapeutics. Since ADC targets do not have to be drivers of tumor growth, ADCs are potentially relevant for a wide range of tumor types. Therefore, we aimed to define the landscape of ADC target expression in a broad range of tumor types.

Methods

PubMed and ClinicalTrials.gov were searched for ADCs that are or were evaluated in clinical cancer trials. Gene expression profiles of 18,055 patient derived tumor samples representing 60 tumor (sub)types and ≥ 3,520 samples representing 22 healthy tissue types were collected from the public domain. Next, we applied FGmRNA-profiling (Fehrmann et al. Nat Genet 2015;47:115-25) to predict per tumor type the overexpression rate at the protein level of ADC targets with healthy tissue samples as reference.

Results

We identified 87 ADCs directed against 59 unique targets. 17 ADC targets showed predicted overexpression of ≥ 75% of samples in at least 1 tumor (sub)type, 38 ≥ 50% and 56 ≥ 25%. A predicted overexpression rate of ≥ 10% of samples for multiple ADC targets was observed for high incidence tumors like breast cancer (n = 31 with n = 23 in triple negative breast cancer), colorectal cancer (n = 18), lung adenocarcinoma (n = 18), squamous cell lung cancer (n = 16) and prostate cancer (n = 5). In rare tumor types we identified targets showing high predicted overexpression, for example in uveal melanomas we found 95% predicted overexpression for c-MET.

Conclusions

This study provides a data driven prioritisation of available ADCs for clinical evaluation in 60 tumor (sub)types. This comprehensive ADC target landscape can support clinicians and drug developers in trial design.

Clinical trial identification

Legal entity responsible for the study

UMCG

Funding

European Research Council advanced grant OnQview to E.G.E. de Vries; the Dutch Cancer Society grant, the NWO-VENI grant and a Mandema Stipendium to R.S.N. Fehrmann

Disclosure

E.G.E. de Vries: Advisory board: Medivation, Merck and Synthon: payments to the institution. Research grants: Amgen, Genentech/Roche, Chugai, Servier, Novartis, Synthon, AstraZeneca, Radius Health, CytomX, Nordic Nanovector: payments to the institution. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.